Furthermore, consistent with the previous studies showing that epigenetic modification-associated proteins, such as HDAC6, EZH2, and H3K4me3, played a vital role in chemoresistance regulation, we also found that OICR-9429 suppressed tumor growth and promoted the chemosensitivity of oxaplatin in CRC cells in vivo, suggesting that the combined treatment of OICR-9429 and oxaliplatin could improve the curative effect and reduce the side effects of original chemotherapy. This evidence concerns the gene EZH2 and colorectal carcinoma.